A group of the most pro-abortion members of the Senate have sent a letter to pro-abortion HHS Secretary Kathleen Sebelius asking her to explain the Obama administration’s decision to deny a request to sell the morning after pill to teens without a prescription.
The FDA originally approved the morning after pill at the end of the Clinton administration in 1999 and, in 2006, it was approved for nonprescription use for women 18 and older. Previously, a federal court ordered the Food and Drug Administration to reconsider its decision preventing minors from purchasing the morning after pill without a prescription.
However, Sebelius said there was not enough information on who the drug affects teens to make the decision. She overturned a ruling by Food and Drug Administrator Margaret Hamburg to allow teens to purchase the morning after pill without a doctor’s involvement, even though the drug may cause an early abortion in some cases.
Now, 14 Democrats, led by pro-abortion Sen. Patty Murray of Washington asked Sebelius to provide more information on the whys and wherefores of the decision, including an explanation for the scientific basis for making it.
“We feel strongly that FDA regulations should be based on science. We ask that you share with us your specific rationale and the scientific data you relied on for the decision to overrule the FDA recommendation,” the letter says. “We ask that you share with us your specific rationale and the scientific data you relied on for the decision to overrule the FDA recommendation. On behalf of the millions of women we represent, we want to be assured that this and future decisions affecting women’s health will be based on medical and scientific evidence.”
Senators signing on to the letter include Kirsten Gillibrand (N.Y.), Barbara Boxer (Calif.), Richard Blumenthal (Conn.), Daniel Akaka (Hawaii), Carl Levin (Mich.), John Kerry (Mass.), Tom Harkin (Iowa), Al Franken (Minn.), Frank Lautenberg (N.J.), Ron Wyden (Ore.), Maria Cantwell (Wash.), Bernie Sanders (I-Vt.), and Jeff Merkley (Ore.).
In a statement concerning her decision, Sebelius said, “The average age of the onset of menstruation for girls in the United States is 12.4 years. However, about ten percent of girls are physically capable of bearing children by 11.1 years of age. It is common knowledge that there are significant cognitive and behavioral differences between older adolescent girls and the youngest girls of reproductive age. If the application were approved, the product would be available, without prescription, for all girls of reproductive age.”
“Because I do not believe enough data were presented to support the application to make Plan B One-Step available over the counter for all girls of reproductive age, I have directed FDA to issue a complete response letter denying the supplemental new drug application (SNDA) by Teva Women’s Health, Inc,” Sebelius continued.
Obama defended the decision and said he wasn’t involved in making it.
Jeanne Monahan, Director of Family Research Council’s Center for Human Dignity, told LifeNews after the decision: “A decision to make Plan B available for girls under the age of 17 without a prescription would not have been in the interest of young women’s health. Secretary Kathleen Sebelius was right to reject the FDA recommendation to make this potent drug available over the counter to young girls. In her own words, the research submitted to the FDA did not include data for all ages for which the drug would be used.”
“Additionally, young people have approximately half of the sexually transmitted diseases (STDs) nationwide, according to the Center for Disease Control and Prevention (CDC). The availability of Plan B over-the-counter for all ages would have bypassed necessary routine medical care for sexually active girls. And a study released in 2010 revealed that adolescent use of Plan B was correlated with an increase in unplanned pregnancies and a high STD rate,” she said.
“There is also the issue of sexual abuse and exploitation. The average age of a girl who is sexually trafficked in the U.S. is 13 to 14. There is a real danger that Plan B could be given to young women, especially sexually abused minors, under coercion or without their consent. Interaction with medical professionals is a major screening and defense mechanism for victims of sexual abuse,” she continued. “Finally, Plan B can act in a way that can destroy life by preventing implantation. Women of all ages have the right to know how this drug may act in their bodies and on their newly developing babies.”
The full text of the letter:
December 13, 2011
The Honorable Kathleen Sebelius
US Department of Health and Human Services
200 Independence Avenue, SW
Washington, DC 20201
Dear Secretary Sebelius,
We are writing to express our disappointment with your December 7, 2011 decision to block the Food and Drug Administration’s (FDA) recommendation to make Plan B One-Step available over-the-counter. We feel strongly that FDA regulations should be based on science. We write to you today to ask that you provide us with the rationale for this decision.
As numerous medical societies and patient advocates have argued, improved access to birth control, including emergency contraception, has been proven to reduce unintended pregnancies. Nearly half of all pregnancies that occur in the United States each year are unintended. Keeping Plan B behind the counter makes it harder for all women to obtain a safe and effective product they may need to prevent an unintended pregnancy.
We ask that you share with us your specific rationale and the scientific data you relied on for the decision to overrule the FDA recommendation. On behalf of the millions of women we represent, we want to be assured that this and future decisions affecting women’s health will be based on medical and scientific evidence.